Lu Chen

Dr. Lu Chen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YTYongtao Tong
Yongtao Tong
YWYuli Wang
Yuli Wang
MYMeiyan Yang
Meiyan Yang
JYJiahui Yang
Jiahui Yang
LCLu Chen
Lu Chen
CGChunsheng Gao
Chunsheng Gao
The purpose of this study is to improve the dissolution and oral bioavailability of an oily drug, vitamin K1 (VK1) by combination of self-nanoemulsifying and liquisolid technologies. The optimal liquid self-nanoemulsifying drug delivery systems (SNEDDS) formulation including VK1 (oil), mixture of soybean lecithin and glycocholic acid (surfactant) and Transcutol HP (cosurfactant) was obtained according to ternary phase diagrams and a central composite design. Based on compatibility, adsorption capacity and dissolution profile, liquid SNEDDS was then solidified on Fujicalin® to form solid SNEDDS by liquisolid technology and compressed directly with excipients into self-nanoemulsifying liquisolid (SNE-L) tablets. Uniform nano-emulsion suspension was formed rapidly when the SNE-L tablets disintegrated in dissolution media and higher drug dissolution was observed compared with the conventional tablets. The results of pharmacokinetic study in beagle dogs showed that the mean Cmax and the area under the curve of SNE-L tablets were remarkably higher than those of conventional tablets, which were consistent with the results of the in vitro dissolution. The relative bioavailability of SNE-L tablets and conventional tablets was approximately 200%. In conclusion, this combination method showed promise to improve the dissolution and oral bioavailability of oily drug vitamin K1.

14 February 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LCLu Chen
Lu Chen
GYGuobao Yang
Guobao Yang
XCXiaoyang Chu
Xiaoyang Chu
CGChunhong Gao
Chunhong Gao
YWYuli Wang
Yuli Wang
CGChunsheng Gao
Chunsheng Gao
Phase-separated films of water-insoluble ethyl cellulose (EC) and water-soluble hydroxypropyl cellulose (HPC) can be utilized to tailor drug release from coated pellets. In the present study, the effects of HPC levels and the pH, type, ionic strength and osmolarity of the media on the release profiles of soluble metoprolol succinates from the EC/HPC-coated pellets were investigated, and the differences in drug-release kinetics in multiple media were further elucidated through the HPC leaching and swelling kinetics of the pellets, morphology (SEM) and water uptake of the free films and the interaction between the coating polymers and the media compositions. Interestingly, the drug release rate from the pellets in different media was not in agreement with the drug solubility which have a positive correlation with the drug dissolution rate based on Noyes–Whitney equation law. In particular, the drug release rate in acetate buffer at pH 4.5 was faster than that in other media despite the solubility of drug was relatively lower, regardless of the HPC levels. It may be attributed to the mutual effect between the EC and acetate buffer, which improved the permeability of the film. In contrast, the release of drug in HCl solution was dependent on the HPC levels. Increasing the levels of HPC increased the effects of hydrogen ions on the polymer of HPC, which resulted in a lower viscosity and strength of the gel, forming the larger size of pores in polymer films, thus increasing the drug diffused from the coating film. Further findings in phosphate buffer showed a reduction in the drug release compared to that in other media, which was only sensitive to the osmolarity rather than the HPC level and pH of the buffer. Additionally, a mathematical theory was used to better explain and understand the experimentally measured different drug release patterns. In summary, the study revealed that the effects of the media overcompensated that of the drug solubility to some extent for controlled-release of the coating polymers, and the drug release mechanism in multiple media depend on EC and HPC rather than on HPC alone, which may have a potential to facilitate the optimization of ideally film-coated formulations.

27 February 2025 in Renal Failure
Verified
Journal Article
Open access
JCJiaojiao Chen
Jiaojiao Chen
YZYanyun Zhang
Yanyun Zhang
YWYinglin Wang
Yinglin Wang
LCLu Chen
Lu Chen
This study evaluates and compares the effectiveness and safety of febuxostat and allopurinol in chronic kidney disease (CKD) stages 3-5 patients with asymptomatic hyperuricemia using a network meta-analysis. A systematic review and network meta-analysis were conducted, adhering to PRISMA-NMA guidelines. Searches included PubMed, Embase, Cochrane Library, and Chinese databases up to June 2024. Randomized controlled trials (RCTs) and cohort studies were assessed for methodological rigor using GRADE. A total of 12 RCTs and 4 cohort studies (n = 2,423 participants) were included. Febuxostat was associated with greater improvements in estimated glomerular filtration rate compared to allopurinol (MD, 4.99 mL/min/1.73 m2; 95%CI -0.65 to 10.78; certainty: low) and placebo (MD, 4.72 mL/min/1.73 m2; 95%CI 0.67 to 8.82; low). Serum uric acid reduction was also more pronounced with febuxostat (MD, -0.61 mg/dL; 95%CI -1.15 to -0.05; moderate). Safety outcomes, including major cardiovascular events and adverse events, showed no significant differences between febuxostat and allopurinol. Subgroup analyses revealed enhanced effectiveness of febuxostat at six months of treatment. This analysis provides robust evidence that febuxostat might offers greater improvements in kidney function and uric acid levels compared to allopurinol or placebo in asymptomatic hyperuricemia with CKD stage 3-5 patients, without compromising safety. These findings can guide clinical decision-making and treatment optimization.

2 October 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
QXQingxia Xue
Qingxia Xue
FWFeixian Wang
Feixian Wang
YZYanyun Zhang
Yanyun Zhang
LCLu Chen
Lu Chen
Background: The potential diabetogenic effects of statins remain controversial, particularly with respect to differences across statin types and doses. Methods: We conducted a network meta-analysis (NMA) of randomized controlled trials (RCTs) to assess the comparative effects of different statins and doses on hyperglycemia-related outcomes. The NMA was performed within a Bayesian framework. PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov were systematically searched from inception to April 2025. Data extraction and verification were independently conducted by two investigators. Outcomes included risk of new-onset diabetes mellitus (NODM), fasting plasma glucose (FPG), 2-h postprandial plasma glucose, and glycated hemoglobin (HbA1c). Separately, we conducted a real-world pharmacovigilance analysis using disproportionality methods based on the FDA Adverse Event Reporting System (FAERS) to identify potential hyperglycemia-related safety signals in patients without diabetes. Results: A total of 22 RCTs, which enrolled 99,311 patients, were included. The NMA found no statistically significant differences in NODM risk among statins or compared with placebo. However, pravastatin 40 mg/day showed a numerically lower risk estimate (OR: 0.86; 95% CrI: 0.50–1.50), whereas rosuvastatin 20 mg/day and atorvastatin 80 mg/day showed relatively higher estimates. Analyses of intermediate glycemic markers, including FPG and HbA1c, revealed no significant differences across all statin regimens and placebo. In parallel, FAERS pharmacovigilance analyses identified disproportionate reporting signals for hyperglycemic events with atorvastatin (ROR: 6.11; 95% CI: 5.94–6.29), rosuvastatin (ROR: 2.44; 95% CI: 2.31–2.58), and simvastatin (ROR: 1.22; 95% CI: 1.13–1.32). Conclusion: No statistically significant differences in glycemic outcomes were observed among individual statins or compared with placebo. However, numerical variations in point estimates across randomized evidence and pharmacovigilance signals suggest possible differences in glycemic profiles among statins. Pravastatin showed numerically lower risk estimates; however, these findings were accompanied by substantial uncertainty. Further prospective studies are needed to clarify these observations.